Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Oscar R. Leeuwenkamp"'
Publikováno v:
EJC Supplements, Vol 16, Iss , Pp 14-23 (2021)
Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state par
Externí odkaz:
https://doaj.org/article/2b1a1faf067f47338bc56d82dd67197e
Autor:
Oscar R Leeuwenkamp, Jayne Palmer
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a relatively rare and heterogenous group of tumors. Currently available treatment options for patients with progressive GEP-NETs include lutetium (177Lu) oxodotreotide (177L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b1d64fe07e4f5ae075f6d1223c2d58
https://doi.org/10.12998/wjcc.v8.i20.4793
https://doi.org/10.12998/wjcc.v8.i20.4793
Autor:
Catherine Watson, Oscar R Leeuwenkamp, Rajaventhan Srirajaskanthan, C.W. Tallentire, John Ramage, Donna Fountain
Publikováno v:
World Journal of Gastroenterology
Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GI-NETs) or the pancreas (P-NETs). They are relatively uncommon, accounting for 2% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c18934ad0fa54d627364462ca82d3e2b
https://doi.org/10.3748/wjg.v26.i25.3686
https://doi.org/10.3748/wjg.v26.i25.3686
Autor:
Jonathan R, Strosberg, Rajaventhan, Srirajaskanthan, Ghassan, El-Haddad, Edward M, Wolin, Beth R, Chasen, Matthew H, Kulke, David L, Bushnell, Martyn E, Caplin, Richard P, Baum, Andrew E, Hendifar, Kjell, Öberg, Philippe, Ruszniewski, Paola, Santoro, Per, Broberg, Oscar R, Leeuwenkamp, Eric P, Krenning
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
We report the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c736b9d8ebf77a75aaed9c1a021b66b
https://pubmed.ncbi.nlm.nih.gov/33771903
https://pubmed.ncbi.nlm.nih.gov/33771903
Publikováno v:
EJC Supplements
Aim To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods A three-state parti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1b39883a97c00835887620f632bc05b5
https://pubmed.ncbi.nlm.nih.gov/34912479
https://pubmed.ncbi.nlm.nih.gov/34912479
Publikováno v:
Schizophrenia Research. 100:108-119
Antipsychotic pharmacotherapy is the standard of care for the treatment of schizophrenia. Although pharmacotherapy effectively improves some symptoms, others can remain. Pharmacotherapy alone also tends to produce only limited improvement in social f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9bb13cffbf5145375d75df3a5cc2f7a
https://doi.org/10.1016/j.schres.2007.12.468
https://doi.org/10.1016/j.schres.2007.12.468
Autor:
Valerie Williams, Oscar R. Leeuwenkamp, Thomas L. Patterson, Mark Price, Robert Morlock, Cheryl D. Hill
Publikováno v:
Current Psychiatry Reviews. 4:28-38
Pharmacotherapy has been reasonably effective in treating positive symptoms associated with schizophrenia and less effective in treating negative symptoms. Humanistic outcomes – quality of life and functionality – are more difficult to assess tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::896120ce37e8071daba07a5eedaf0a8a
https://doi.org/10.2174/157340008783743839
https://doi.org/10.2174/157340008783743839
Publikováno v:
The Journal of Clinical Pharmacology. 36:639-646
An open, randomized, three-period crossover study was conducted to compare the steady-state pharmacokinetics, pharmacodynamics, and tolerability of concomitant administration of BAY x 1005 and theophylline in 12 healthy volunteers. BAY x 1005 (250 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaefdebb8b7cae88c0d3ad909fdab199
https://doi.org/10.1002/j.1552-4604.1996.tb04229.x
https://doi.org/10.1002/j.1552-4604.1996.tb04229.x
Autor:
J. Coen Netelenbos, Petra J. M. Elders, Floris C. van Ginkel, Oscar R. Leeuwenkamp, Wil H. L. Hackeng, Paul Lips, Paul F. van der Stelt, Edwin Khoe
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 73(3), 533-540. The Endocrine Society
Elders, P J M, Netelenbos, J C, Lips, P, Ginkel, F C V, Khoe, E, Leeuwenkamp, O R, Hackeng, W H L & Stelt, P F V D 1991, ' Calcium supplementation reduces vertebral bone loss in perimenopausal women: A controlled trial in 248 women between 46 and 55 years of age ', Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 3, pp. 533-540 . https://doi.org/10.1210/jcem-73-3-533
Elders, P J M, Netelenbos, J C, Lips, P, Ginkel, F C V, Khoe, E, Leeuwenkamp, O R, Hackeng, W H L & Stelt, P F V D 1991, ' Calcium supplementation reduces vertebral bone loss in perimenopausal women: A controlled trial in 248 women between 46 and 55 years of age ', Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 3, pp. 533-540 . https://doi.org/10.1210/jcem-73-3-533
To study the effect of calcium supplementation on perimenopausal bone loss, 295 women were randomized into a control group and 2 supplementation groups receiving, respectively, 1000 and 2000 mg elemental calcium/day for a period of 2 yr. We observed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6806995d866758c4eb6785aa064fb25c
https://doi.org/10.1210/jcem-73-3-533
https://doi.org/10.1210/jcem-73-3-533
